Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Fuji
Chubb
Fish and Richardson
Healthtrust
Baxter
US Department of Justice
Novartis
Harvard Business School
Daiichi Sankyo

Generated: February 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,859,037

« Back to Dashboard

Summary for Patent: 5,859,037
Title: Sulfonylurea-glitazone combinations for diabetes
Abstract:Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating diabetes mellitus and improving glycemic control.
Inventor(s): Whitcomb; Randall Wayne (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:08/970,057
Patent Claims: 1. A composition comprising from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent and from about 100 mg to about 1000 mg of a glitazone antidiabetic agent, said amounts of sulfonylurea and glitazone being synergistic for the treatment of non-insulin dependent diabetes mellitus in humans.

2. A composition of claim 1 wherein the sulfonylurea is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide.

3. A composition of claim 2 wherein the glitazone is selected from troglitazone, ciglitazone, pioglitazone, englitazone, TA 174, and BRL 49653.

4. A composition of claim 3 comprising troglitazone and glyburide.

5. A method of treating non-insulin dependent diabetes mellitus in humans comprising administering to a patient in need of treatment from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent in combination with about 100 mg to about 1000 mg of a glitazone antidiabetic agent, wherein said amounts are synergistic in the treatment of non-insulin dependent diabetes mellitus.

6. A method according to claim 5 wherein the sulfonylurea antidiabetic agent is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclozide, gliquidone, glyhexamide, phenbentamide, and tolcyclamide.

7. A method according to claim 6 wherein the glitazone antidiabetic agent is selected from troglitazone, ciglitazone, pioglitazone, englitazone, TA 174, and BRL 49653.

8. A method according to claim 7 comprising a combination of glyburide and troglitazone.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKinsey
Cantor Fitzgerald
UBS
Deloitte
Baxter
Queensland Health
Chubb
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot